Corcept Therapeutics (CORT) Cost of Revenue (2012 - 2026)

Corcept Therapeutics has disclosed Cost of Revenue across 15 years of filings, most recently posting $2.9 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $2.9 million, up 19.98% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.5 million (up 25.18% YoY), and the FY2025 annual result was $13.0 million, up 19.25% from the prior year.
• Cost of Revenue came in at $2.9 million for Q1 2026 at Corcept Therapeutics, up from $2.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $4.6 million in Q3 2025 to a low of $1.2 million in Q1 2022.
• The 5-year median for Cost of Revenue is $2.4 million (2025), against an average of $2.3 million.
• Across the five-year window, Cost of Revenue jumped 82.9% in 2024 and decreased 13.9% in 2025, its largest moves.
• Corcept Therapeutics' Cost of Revenue stood at $1.5 million in 2022, then gained by 26.82% to $1.9 million in 2023, then surged by 57.49% to $3.0 million in 2024, then fell by 13.9% to $2.5 million in 2025, then advanced by 13.28% to $2.9 million in 2026.
• The last three Cost of Revenue figures came in at $2.9 million (Q1 2026), $2.5 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.